Led · Seed · Mar 2026

iDEL Therapeutics develops a synthetic shuttle technology that evades endosomal trapping to deliver high intracellular exposure and sustained tumor retention of therapeutic payloads. The platform is compatible with both large and small molecules, including nanobodies against oncogenes and tumor-targeted cytotoxic payloads. The company leverages a pan-cancer uptake mechanism to move drug payloads directly into the cytosol of tumor cells in patients. iDEL is led by CEO Marcus Kostka and is based in Dortmund, Germany. Following its €9M Seed raise, the company plans to expand operations and continue its development efforts. No revenue, user, or other operating metrics were disclosed in the announcement.

Led · Series A · Dec 2025

T-Curx is a spin-out from the University Clinics Würzburg that is building a pipeline of next-generation CAR-T cell therapies produced with virus-free, Sleeping-Beauty transposon gene-transfer technology. The platform is designed to enable scalable, cost-effective manufacturing and to open the door to in-vivo CAR-T generation. The company is initially advancing clinical candidates for acute myeloid leukemia (AML) and solid tumor indications. Proceeds from its recent Series A financing will accelerate these clinical programs and further develop the proprietary non-viral technologies. Led by CEO Ulf Grawunder, PhD, and Prof. Michael Hudecek, T-Curx aims to deliver more accessible and effective cell-based cancer treatments. The $20 million raise marks the company’s first institutional round, providing runway for near-term clinical milestones.

Led · Series C · Sep 2024

ImmunOs Therapeutics leverages an HLA-based technology platform to develop first-in-class therapeutics targeting cancer and autoimmune diseases. Its lead program, IOS-1002, is a multi-functional HLA-fusion protein that binds specific LILRB and KIR receptors to stimulate both the innate and adaptive immune systems. The company is developing IOS-1002 as a cancer therapeutic intended to eliminate tumor cells and is also exploring different modalities to agonize receptors for autoimmune disease modulation. ImmunOs is advancing IOS-1002 through a Phase Ia dose-escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). The company is led by Executive Chairman Reinhard Ambros and is based in Schlieren, Switzerland. ImmunOs Therapeutics AG leverages an HLA-based technology platform to develop first-in-class therapeutics for cancer and autoimmune diseases. Its lead program, IOS-1002 (formerly iosH2), is a multi-functional fusion protein based on a naturally occurring HLA that targets LILRB1, LILRB2 and KIR3DL1 and synergizes with the adaptive immune system to drive anti-tumor activity. A Phase 1 clinical trial for IOS-1002 is planned to start in the second half of 2022, and the company intends to progress the program through Phase 2. ImmunOs is also developing antibodies to block activation of specific HLA proteins associated with autoimmune diseases and is advancing additional oncology and autoimmune programs toward clinical development. The company has established a U.S. subsidiary to expand its international reach, execute future U.S. clinical trials, and strengthen transatlantic operations and team. ImmunOs Therapeutics AG is a Swiss biotechnology company developing a new class of HLA-based biologic therapeutics for cancer and autoimmune diseases. Its proprietary R&D platform creates HLA-based therapeutics that address multiple targets via a single fusion protein; the company's lead program is a multifunctional fusion protein that blocks specific LILRB receptors to activate anti-tumor responses. ImmunOs is also developing a novel HLA‑open conformer‑specific monoclonal antibody, OCi, intended to treat immune-mediated inflammatory diseases and to act upstream of current therapies. The company plans in vivo proof-of-concept studies in spondyloarthritis and intends to extend OCi development to psoriasis and inflammatory bowel disease following successful results. Research is being conducted through an international consortium with ProteoGenix SAS (optimizing phage display for HLA mAb development) and Amsterdam UMC (providing animal models and clinical expertise). ImmunOs has received public funding from the EU’s Eurostars-2 programme and the Swiss Innovation Agency Innosuisse and is supported by investors including Pfizer Ventures, BioMed Partners and Redalpine. ImmunOs Therapeutics AG develops novel human immunomodulatory proteins that act on the innate immune system to activate anti-tumor responses. Its lead program is the iosH platform, with lead agent iosH2 being advanced as a potential treatment for both solid and liquid tumors. The company’s approach builds on research into HLA open conformer modulation of immune cells and targets diverse immunoregulatory receptors to modulate the tumor microenvironment. ImmunOs plans to complete first-in-human trials of iosH2 and to broaden the iosH platform by advancing additional preclinical programs in cancer and auto-immunity. The company is a spin-off of the University of Zurich and the University of Basel. Leadership includes CEO Sean R. Smith and CSO and co-founder Dr. Osiris Marroquin Belaunzaran, and the company states its mission is to develop novel therapeutics to improve the lives of patients with serious disease. ImmunOs Therapeutics AG is a Swiss biotechnology spin-off of the University of Zurich and University of Basel developing a next-generation platform of multitasking human immunomodulatory proteins for cancer. Its lead clinical candidate is a single multitasking protein agent aimed at treating solid tumors. The platform targets diverse immunoregulatory receptors to activate anti-tumor responses, working directly on the innate immune system (MDSCs, macrophages, NK cells and neutrophils) and indirectly on the adaptive system by enabling T cell expansion. ImmunOs positions its proteins for use both as monotherapy and in combination with checkpoint inhibitors (PD-1, CTLA-4, PD-L1) and costimulatory agonists (e.g., 4-1BB). The team brings experience in drug development and global commercialization in immunotherapy, immunology, and oncology. Proceeds from the announced financing will be used to advance the lead clinical candidate.

Participated · Series B · Mar 2024

Tubulis is a Munich-based biotechnology company engineering uniquely matched antibody-drug conjugates with enhanced biophysical properties for improved on-tumor delivery and wider therapeutic windows. Its proprietary Tubutecan and other ADC platform technologies underpin a growing pipeline designed for high-need solid tumor indications. The lead program, TUB-040 targeting NaPi2b, has shown early clinical proof-of-concept in platinum-resistant high-grade serous ovarian cancer, demonstrating anti-tumor activity at low doses with favorable safety. A second clinical-stage candidate, TUB-030, targets 5T4, and several additional ADCs remain in preclinical development. Proceeds from the company’s latest financing will fund pivotal trials of TUB-040, evaluations in earlier-line ovarian cancer, combination regimens and broader solid tumor exploration. The capital will also advance TUB-030 and preclinical assets while driving further innovation of Tubulis’ ADC technologies for internal programs and partnerships. To date, the firm has secured €344 million (US $401 million) in Series C funding from a global syndicate of life-science investors.

Led · Series A · Sep 2023

TOLREMO therapeutics focuses on preventing non-genetic cancer drug resistance by dismantling cancer's earliest defense mechanisms to targeted therapies. Its lead clinical candidate, TT125-802, is an orally available small-molecule CBP/p300 bromodomain inhibitor designed to block transcriptional resistance pathways that drive early therapy escape. The company plans to initiate a Phase 1 monotherapy dose-escalation study to evaluate safety, pharmacokinetics, pharmacodynamics, and early signs of efficacy across solid tumor indications. Stepwise development will advance TT125-802 into combination studies with targeted agents such as KRAS, EGFR, or AR inhibitors in specific advanced solid tumors. TOLREMO positions its approach as a platform to improve response rates and durability of existing targeted treatments. The company is based in Basel, Switzerland, and has strengthened its leadership and advisory team alongside its clinical and development plans. TOLREMO is a Swiss biotech developing resistance‑preventing precision therapies that aim to complement standard cancer treatments. The company uses a proprietary drug discovery engine to identify novel drug‑resistance regulators and to develop small‑molecule therapies against those targets. Its therapies are designed to improve response rates, extend survival and enhance quality of life for cancer patients. Thanks to a Series A second closing, TOLREMO has secured additional capital to advance programs. The new funds are dedicated to development of the company’s first clinical candidate and to further strengthening its preclinical pipeline of resistance‑preventing assets. Stefanie Flückiger‑Mangual serves as CEO and co‑founder and commented on the financing and strategic progress. Tolremo Therapeutics is a Swiss biotechnology company advancing a science-based drug discovery and development pipeline focused on the molecular mechanisms of cancer and drug resistance. Founded in March 2017 as an ETH spin-off by Dr. Stefanie Flückiger-Mangual, Prof. Dr. Wilhelm Krek, Prof. Dr. Karl-Heinz Altmann, Dr. Isaac Kobrin and Emmanuel Savioz, the company leverages the founders' expertise in medicinal chemistry and pharmaceutical development. Its core programs comprise two major drug development programs aimed at preventing drug resistance in cancer therapies. Tolremo intends to use proceeds from the financing to further advance those programs. The company completed a CHF 9.0m (USD $9.3m) Series A financing. In conjunction with the funding the company strengthened its board by adding Dr. Erich Greiner, Prof. em. Thomas Cerny and Dr. Andreas Wallnöfer. TOLREMO is a biotech spin-off from ETH Zurich focused on preventing drug resistance in cancer therapy through science-based drug discovery and development. The company has developed a unique drug screening platform for which a patent has been filed. The platform is used both to discover novel anti-drug-resistance molecules and to identify new combinations of approved drugs to prevent resistance. TOLREMO plans to advance its discovery and development efforts and reach several key milestones within the next 12 to 18 months. The company benefits from access to ETH infrastructure, including laboratory space and an industry-standard robotic screening facility on the ETH Hönggerberg campus. Founded in March 2017, TOLREMO is led by CEO and co-founder Dr. Stefanie Flückiger-Mangual.